WG
MRTX

Winton Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Winton Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,229
Closed -$269K – 1182
2023
Q1 		$269K Sell
7,229
-580
-7% -$26.1K 0.02% 848
2022
Q4 		$354K Buy
7,809
+911
+13% +$59K 0.02% 744
2022
Q3 		$482K Sell
6,898
-1,001
-13% -$74.1K 0.03% 651
2022
Q2 		$530K Buy
7,899
+1,422
+22% +$90.4K 0.03% 679
2022
Q1 		$533K Buy
6,477
+4,922
+317% +$503K 0.03% 663
2021
Q4 		$228K Sell
1,555
-3,159
-67% -$490K 0.01% 913
2021
Q3 		$834K Sell
4,714
-419
-8% -$67.4K 0.05% 593
2021
Q2 		$829K Sell
5,133
-970
-16% -$156K 0.04% 635
2021
Q1 		$1.04M Sell
6,103
-493
-7% -$97.6K 0.06% 434
2020
Q4 		$1.45M Sell
6,596
-14,216
-68% -$3.07M 0.1% 228
2020
Q3 		$3.46M Buy
+20,812
New +$2.85M 0.11% 266
2019
Q1 		– Sell
-7,300
Closed -$310K – 1213
2018
Q4 		$310K Buy
7,300
+1,787
+32% +$71.2K 0.01% 646
2018
Q3 		$260K Buy
+5,513
New +$307K 0.01% 878

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Winton Group's MRTX Position: Q2 2023 in Review

Winton Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 7,229 shares — an estimated $269K sold.

Winton Group first reported a position in MRTX in Q3 2018 and held it in 13 quarters. The position peaked at $3.46M in Q3 2020. 205 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

  • Winton Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Winton Group sold 7,229 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $269K.
  • Winton Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2018 and held it in 13 quarters.
  • Winton Group's Mirati Therapeutics, Inc. Common Stock position peaked at $3.46M in Q3 2020.
  • 205 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Winton Group's 13F filing for Q2 2023, filed 14 Aug 2023.